Description of the upcoming change in data analysis for USP dissolution performance verification tests

Walter W. Hauck, Anthony J. DeStefano, William E. Brown, Erika S. Stippler, Darrell R. Abernethy, Roger L. Williams, Thomas S. Foster, James E. Polli, Diane J. Burgess, G. Bryan Crist, Mario A. Gonzalez, Vivian A. Gray, Johannes Kraemer, Lewis J. Leeson, Alan F. Parr, Leon Shargel, Eli Shefter, W. Craig Simon, Nhan L. Tran, Clarence T. Ueda

Research output: Contribution to journalArticlepeer-review

Abstract

As part of its evaluation of the performance verification tests used periodically to affirm the integrity of the USP Performance test when General Chapter Dissolution (711) is relied upon, the Biopharmaceutics Expert Committee of the Council of Experts, working with staff, decided to change the form of the accept/reject decision from one based on the result for each tablet to one based on the mean and coefficient of variation of results from a set of tablets. This paper describes the new approach. The paper also describes an implementation period for the approach, coupled with a period during which USP will discontinue use of the Salicylic Acid tablet in a performance verification test.

Original languageEnglish (US)
Pages (from-to)1630-1634
Number of pages5
JournalPharmacopeial Forum
Volume34
Issue number6
StatePublished - Nov 1 2008

ASJC Scopus subject areas

  • Pharmacy
  • Pharmacology
  • Drug guides

Fingerprint Dive into the research topics of 'Description of the upcoming change in data analysis for USP dissolution performance verification tests'. Together they form a unique fingerprint.

Cite this